Literature DB >> 7657281

Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure.

H J Zimmerman1, W C Maddrey.   

Abstract

Hepatic injury in alcoholics due to intake of acetaminophen (APAP or acetylparaaminophenol) with therapeutic intent has been reported, but the extent of the phenomenon is not clear, pertinent details of the association remain insufficiently clarified, and the importance of the phenomenon is not widely appreciated. The present report describes 67 patients who developed hepatic injury after ingestion of APAP with therapeutic intent. All were regular users of alcohol. Sixty-four percent of the patients were considered to be "alcoholic" or reported intakes greater than 80 g/d, 35% took 60 g/d or less, and the remainder were vague in their reporting. Doses of APAP were in the "nontoxic" range ( < 6 g/d) in 60% of the group, within the recommended range ( < 4 g/d) in 40%, and at 4.1 to 6 g/d in 20%. Characteristic feature was the towering level reached by aspartate transaminase (AST) with figures ranging from 3,000 to 48,000 IU in more than 90% of cases. Almost 20% of the patients died. The data on these patients were similar to 94 cases of injury from APAP taken with therapeutic intent reported in the literature. This study provides further evidence of hepatic injury in regular uses of alcohol, especially chronic alcoholics, who take APAP with therapeutic intent. Susceptibility is presumably caused by induction of cytochrome P-4502EI by ethanol and by depletion of glutathione (GSH) because of the effects of alcohol, the malnutrition often associated with alcoholism, and the depletion associated with chronic use of APAP and impaired glucuronidation caused by fasting perhaps as well. The syndrome of liver injury is distinctive, marked by uniquely elevated levels of AST, and poses a significant threat.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657281

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  70 in total

1.  Drug use for non-hepatic associated conditions in patients with liver cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2003-04-09       Impact factor: 2.953

Review 2.  Pharmacotherapy for pain in rheumatologic conditions: the neuropathic component.

Authors:  Keri L Fakata; Arthur G Lipman
Journal:  Curr Pain Headache Rep       Date:  2003-06

Review 3.  Anti-inflammatory agents for the treatment of musculoskeletal pain and arthritis.

Authors:  Keri L Fakata
Journal:  Curr Pain Headache Rep       Date:  2004-06

4.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 5.  Implementation of a standardized pain management in a pediatric surgery unit.

Authors:  B Messerer; A Gutmann; A Weinberg; A Sandner-Kiesling
Journal:  Pediatr Surg Int       Date:  2010-07-13       Impact factor: 1.827

Review 6.  Drug-induced liver disorders: implications for drug development and regulation.

Authors:  N Kaplowitz
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  "Unintentional" acetaminophen overdose on the rise: who is responsible? Dr Robert J Fontana is interviewed by Paul C Adams.

Authors:  Robert J Fontana
Journal:  Can J Gastroenterol       Date:  2006-05       Impact factor: 3.522

Review 8.  Adverse drug reactions.

Authors:  M Pirmohamed; A M Breckenridge; N R Kitteringham; B K Park
Journal:  BMJ       Date:  1998-04-25

Review 9.  Paracetamol hepatotoxicity: how to prevent.

Authors:  J G O'Grady
Journal:  J R Soc Med       Date:  1997-07       Impact factor: 5.344

Review 10.  Drug-induced acute liver failure.

Authors:  William M Lee
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.